CRISPR and CRISPR-Associated (Cas) Genes market was valued at US$ 1863.6 million in 2022 and is anticipated to reach US$ 9813.2 million by 2029, witnessing a CAGR of 31.9% - Valuates Reports

CRISPR and CRISPR-Associated (Cas) Genes market was valued at US$ 1863.6 million in 2022 and is anticipated to reach US$ 9813.2 million by 2029, witnessing a CAGR of 31.9% during the forecast period 2023-2029.

Get sample report - https://reports.valuates.com/request/sample/QYRE-Auto-39I6706/China_CRISPR_and_CRISPR_Associated_Cas_Genes_Market_Report_Forecast_2021_2027

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.
CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

Segment by Type
Genome Editing
Genetic engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering

Segment by Application
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes

Get detailed report - https://reports.valuates.com/market-reports/QYRE-Auto-39I6706/china-crispr-and-crispr-associated-cas-genes

Similar report -

https://reports.valuates.com/market-reports/QYRE-Auto-3H3085/global-crispr-technology

https://reports.valuates.com/market-reports/QYRE-Auto-35K14121/global-crispr-based-therapeutics

https://reports.valuates.com/market-reports/QYRE-Auto-11A9693/global-plant-breeding-and-crispr-plants

Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137

Email Id:
Please reach us at sales@valuates.com

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.